Nothing Ventured

About Nothing Ventured

In conversation with the people who make the start-up world go round. Join Aarish Shah as he talks to founders, investors, and operators across the tech and venture ecosystem exploring some of the lesser-heard stories and challenges they've faced as they try to build the future.https://nothingventured.tech/Follow Nothing Ventured on socialTwitter https://twitter.com/NVPodFacbook https://www.facebook.com/NothingVenturedPodTikTok https://www.tiktok.com/@nothingventuredpodInstagram https://www.instagram.com/nothingventuredpod/

Publisher

Aarish Shah - EmergeONE

Category

business

Language

en

Explicit

No

First episode

14 Jul 2021

Latest episode

29 Oct 2026

Latest episodes

1 of 295 episodes have a transcript.

1. 

   29 Oct 2026

   AI Capital, Secondaries where Liquidity Sits | Nothing Ventured News

   Who’s actually getting paid in venture right now? AI capital is still flowing, but investors are asking tougher questions about infrastructure spending, defensible moats and how founders and funds get liquidity. In this episode of Nothing Ventured News, host Aarish breaks down the latest developments across global and UK venture capital, including: 🚀 Q3 venture funding and the AI capital boom 🧠 AI infrastructure spending, moats and the question of who gets paid 🛰️ The reported exploratory SpaceX and Tesla merger talks and the governance questions they raise 💳 A weak quarter for fintech funding and the rise of agentic commerce 🛡️ Hard tech, defence-adjacent software and the DPI pressure on VCs 📈 Why secondaries and tender offers are becoming a major source of liquidity 🇬🇧 New EIS and VCT limits and a capital gains tax prediction ahead of the 28 October budget From AI infrastructure and fintech to secondary markets and UK tax policy, this episode explores where the money is flowing and what founders and investors need to be watching next. 🎙️ Nothing Ventured News Hosted by Aarish Shah. This episode is sponsored by EmergeOne, fractional CFOs for venture backed tech startups from Seed to Series B. Get in touch at https://emergeone.co.uk/contact-us/ or join the CFO team at https://emergeone.co.uk/join-the-cfo-team/ #VentureCapital #AI #Startups #VC #Fintech #DeepTech #PrivateMarkets #Secondaries #EIS #VCT #UKStartups #UKBudget #Entrepreneurship #VentureCapitalUK

2. 

   22 Oct 2026

   Can This Technology Stop Medical Device Infections? | Georgia Fleet

   In this episode of Nothing Ventured, Aarish Shah sits down with Dr Georgia Fleet, co-founder of Zonova, to explore antimicrobial technology, medical device innovation and the challenges of commercialising deep tech. Georgia shares her journey from materials science to founding Zonova, which is developing Z-ROS, an antimicrobial technology designed to kill microbes on contact when integrated into medical devices. She explains how the company pivoted from animal health to human healthcare and why a B2B licensing model was key to its commercial strategy and fundraising. The conversation explores raising venture capital as a female founder, navigating medical device regulation, proving safety and efficacy, and knowing when customer pilots become a distraction. Georgia also discusses building a business with a friend as co-founder and introducing AI into a science-led company despite initially being a sceptic. In this episode: - Antimicrobial technology and medical device infections - Dr Georgia Fleet's journey into deep tech - Building Zonova and developing Z-ROS - Pivoting from animal health to human healthcare - Licensing versus manufacturing - Raising venture capital as a female founder - Medical device regulation and commercialisation - Proving safety and efficacy - Customer pilots and commercial strategy - Building a business with a friend - AI adoption in a science-led company - Turning scientific breakthroughs into scalable businesses Find Dr Georgia Fleet: LinkedIn: https://uk.linkedin.com/in/georgiafleet Zonova: https://zonovatech.com/ LinkedIn: https://www.linkedin.com/company/zonovatech/ 🎙️ Listen to Nothing Ventured for conversations with founders, investors and the people shaping the future of technology and venture capital. #NothingVentured #VentureCapital #DeepTech #MedTech #AntimicrobialTechnology #MedicalDevices #HealthcareInnovation #Startups #WomenInTech #Entrepreneurship

3. 

   15 Oct 2026

   AI, Drug Discovery & The Future of Healthcare | Romain Clément

   In this episode of Nothing Ventured, Aarish Shah sits down with Romain Clément, founder of AKA Science, to explore how AI, clinical data and drug discovery could transform the pharmaceutical industry. Romain shares the personal story behind AKA Science, following his own brain tumour diagnosis and the three years of research that led him from literature and philosophy into healthcare, pharmaceuticals and AI. He explains how the company has built technology designed to structure complex scientific data and uncover potential treatment options that might otherwise remain hidden. The conversation explores why having more data doesn't necessarily create more value for pharma, and why the real challenge is often the structure, quality, context and usability of that data. Romain explains how AKA Science approaches unstructured scientific information, clinical data and AI to identify connections and potential treatment pathways. They also discuss drug repurposing, off-label treatments and how existing drugs could potentially be identified for different patient groups and conditions. Romain explains how AKA Science aims to connect the interests of patients and pharmaceutical companies by uncovering opportunities within existing drug portfolios. The discussion then moves into AI, European technology and sovereignty. Romain shares his perspective on Europe's ability to compete with the US and China, the importance of compute and data centres, open-weight models, regulation and why Europe needs to move faster if it wants to remain competitive in the AI race. They also explore Europe's strengths in scientific research and early-stage innovation, alongside the challenges of commercialisation, bureaucracy and turning research breakthroughs into scalable companies. Finally, Romain explains why AKA Science prioritised scientific rigour, industry trust and profitability rather than following the traditional venture-backed growth model, and shares his contrarian belief that the first immortal person may already have been born. In this episode: AI and the future of drug discovery Romain Clément's journey from brain tumour patient to founder Building AKA Science AI and pharmaceutical research Clinical data and scientific knowledge Why big data failed pharma Structuring and contextualising scientific data AI-powered drug discovery Drug repurposing and off-label treatments Finding overlooked treatment options Connecting patients and pharmaceutical companies Healthcare innovation and patient outcomes Data quality, noise and serendipity AI, compute and data centres Open-weight vs closed-weight AI models European AI sovereignty The US, China and Europe's AI race Regulation vs technological progress Europe's strengths in scientific research Commercialising European innovation Bureaucracy and the pace of innovation Building a healthcare technology company Profitability vs venture capital Trust and validation in pharma Scientific rigour and industry expertise The future of AI and healthcare Healthspan, longevity and immortality Find Romain Clément and AKA Science online at: AKA Science: https://akascience.com/ 🎙️ Listen to Nothing Ventured for conversations with founders, investors and the people shaping the future of technology and venture capital. #AI #ArtificialIntelligence #DrugDiscovery #Pharma #HealthcareAI #HealthTech #Biotech #Pharmaceuticals #DeepTech #VentureCapital #Startups #DrugRepurposing #ClinicalResearch #AIInnovation #HealthcareInnovation

Inside a recent episode

Renan Devillieres: From Tesla Factories to Software Disruption | Episode 22

Published 21 Mar 2024 · Transcript excerpt

[…] Amazing. And if you think about three ventures that you're excited about, either inside or outside of your portfolio, what would they be? I would choose two inside my portfolio and one outside. In my portfolio, there is a full -speed automation. Full -speed automation is a company that lets you program robots just with voice. And so you say, pick the blue box and the robots auto programs itself recognize the blue box and go and pick the blue box. So that would be one. Another one that I love is called WasteX and it's managing industrial waste at scale for industrial companies. And so making sure that it's better used, sent to the right companies to make the most to use and the reason. […]

Who has been a guest on Nothing Ventured

Names identified in recent episode analyses. Showing up to five guests.

• Anton Backman
• Meryem Arik
• Kris Naudts
• Zeynep Koruturk
• Omer Omar

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

YouTube views

377,672

Score snapshot 15 Sept 2025

Apple Podcasts (US)

4.0 / 5

4 ratings

Spotify

5.0 / 5

6 ratings

Podcast Authority Score: 83 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

98

Social presence

0

YouTube

93

Engagement

76

Contact Nothing Ventured

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.

Questions about Nothing Ventured